Oramed Pharmaceuticals (ORMP) Non-Current Deferred Tax Liability (2025 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Non-Current Deferred Tax Liability came in at $17.7 million in Q1 2026, up 124.33% on a QoQ basis from $7.9 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $17.7 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $17.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.7 million (changed N/A YoY) and the FY2025 annual result came in at $7.9 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability rose to $17.7 million in Q1 2026, from $7.9 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $17.7 million in Q1 2026 to a low of $7.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.54 Mn |
| Jun 30, 2026 | 39.54 Mn |
| Mar 31, 2026 | 17.75 Mn |
| Mar 31, 2026 | 17.75 Mn |
| Dec 31, 2025 | 7.91 Mn |
| Dec 31, 2025 | 7.91 Mn |
| Sep 30, 2025 | 7.92 Mn |
| Sep 30, 2025 | 7.92 Mn |